+

PE20010066A1 - Polipeptido de proteina c activada - Google Patents

Polipeptido de proteina c activada

Info

Publication number
PE20010066A1
PE20010066A1 PE2000000398A PE0003982000A PE20010066A1 PE 20010066 A1 PE20010066 A1 PE 20010066A1 PE 2000000398 A PE2000000398 A PE 2000000398A PE 0003982000 A PE0003982000 A PE 0003982000A PE 20010066 A1 PE20010066 A1 PE 20010066A1
Authority
PE
Peru
Prior art keywords
substituted
amino acids
protein
thr
sequence
Prior art date
Application number
PE2000000398A
Other languages
English (en)
Spanish (es)
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010066A1 publication Critical patent/PE20010066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
PE2000000398A 1999-04-30 2000-04-27 Polipeptido de proteina c activada PE20010066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13180199P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
PE20010066A1 true PE20010066A1 (es) 2001-02-02

Family

ID=22451086

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000398A PE20010066A1 (es) 1999-04-30 2000-04-27 Polipeptido de proteina c activada

Country Status (11)

Country Link
EP (1) EP1090130A1 (fr)
JP (1) JP2002542832A (fr)
KR (1) KR20010053345A (fr)
AR (1) AR029627A1 (fr)
AU (1) AU4188500A (fr)
BR (1) BR0006088A (fr)
CA (1) CA2338799A1 (fr)
HU (1) HUP0102444A3 (fr)
IL (1) IL140326A0 (fr)
PE (1) PE20010066A1 (fr)
WO (1) WO2000066754A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131091B1 (fr) * 1998-11-20 2003-04-02 Eli Lilly And Company Traitement des fievres virales hemorragiques avec de la proteine c
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
WO2001057193A2 (fr) * 2000-02-02 2001-08-09 Eli Lilly And Company Derives de proteine c
CA2400187A1 (fr) 2000-02-11 2001-08-16 Eli Lilly And Company Derives de la proteine c
AU2001292308A1 (en) * 2000-09-30 2002-04-15 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hemolytic anemia
AU2002210388B2 (en) * 2000-10-18 2006-11-23 Perseid Therapeutics Llc Protein C or activated protein C like molecules
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2006044294A2 (fr) * 2004-10-14 2006-04-27 Eli Lilly And Company Analogues de la proteine humaine c
WO2023171719A1 (fr) * 2022-03-08 2023-09-14 学校法人自治医科大学 Séquence de protéine c activée
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113878T3 (es) * 1989-12-29 1998-05-16 Zymogenetics Inc Proteina c hibrida.
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
EP0946715B1 (fr) * 1996-11-08 2006-03-29 Oklahoma Medical Research Foundation Utilisation d'une proteine c modifiee

Also Published As

Publication number Publication date
JP2002542832A (ja) 2002-12-17
KR20010053345A (ko) 2001-06-25
CA2338799A1 (fr) 2000-11-09
EP1090130A1 (fr) 2001-04-11
HUP0102444A2 (hu) 2001-10-28
WO2000066754A1 (fr) 2000-11-09
IL140326A0 (en) 2002-02-10
HUP0102444A3 (en) 2003-09-29
AR029627A1 (es) 2003-07-10
BR0006088A (pt) 2001-03-20
AU4188500A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
Ouellette et al. Purification and primary structure of murine cryptdin‐1, a Paneth cell defensin
Andreu et al. N-terminal analogs of cecropin A: synthesis, antibacterial activity, and conformational properties
Jang et al. Halocidin: a new antimicrobial peptide from hemocytes of the solitary tunicate, Halocynthia aurantium
RU2017135599A (ru) Белки, специфичные в отношении cd137
PE20010066A1 (es) Polipeptido de proteina c activada
CY1112228T1 (el) Τροποποιημενο πολυπεπτιδιο επικρατειας kunitz
MX9606536A (es) Proteinas n-terminalmente extendidas expresadas en levaduras.
ATE417595T1 (de) Keratin-bindende polypeptide
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
DE112006000677A5 (de) Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
DE60137587D1 (de) Antimikrobielle peptide und deren verwendung
ATE525082T1 (de) Compstatin-analoga mit verbesserter wirkung
AR058429A1 (es) Plantas de girasol resistentes a herbicidas, polinucleotidos que codifican proteinas de subunidad mayor de acetohidroxiacido sintetasa resistentes a herbicidas y metodos de uso
BRPI0512286A (pt) proteìnas quiméricas inibidoras da angiogênese e o uso
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
Osipov et al. Cobra venom contains a pool of cysteine-rich secretory proteins
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
DK110485A (da) Rensning, kloning og karakterisering af genet for interleukin 1
Schmelzer et al. Biochemical characterization of recombinant human nerve growth factor
DE69819505D1 (de) Mit smad wechselwirkende polypeptide und verwendungen davon
Satake et al. Rapid and efficient identification of cysteine-rich peptides by random screening of a venom gland cDNA library from the hexathelid spider Macrothele gigas
Balaji et al. Purification, structure determination and synthesis of covalitoxin-II, a short insect-specific neurotoxic peptide from the venom of the Coremiocnemis validus (Singapore tarantula)
BRPI0613676A2 (pt) polipeptìdeo, seu uso e composição farmacêutica compreendendo o mesmo
Sheng et al. Expression and characterization of a fibrinogenolytic enzyme from horsefly salivary gland
ATE521635T1 (de) Physiologisch wirksamer komplex mit tnf aktivität

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载